Table 1 : Clinical Trials of Combination Regimens with Immune Checkpoint Inhibitors in Breast Cancer.


Intervention Study
Phase
Patient Population Estimated Study
Completion
Clinical Trials.gov
Identifier

Immunotherapy and chemotherapy

Nab-paclitaxel with or without Atezolizumab III metastatic TNBC May 2017 NCT02425891
Carboplatin and Nab-paclitaxel with or without 
Atezolizumab
III neoadjuvant TNBC June 2022 NCT02620280
Atezolizumab with Nab-paclitaxel II neoadjuvant TNBC February 2021 NCT02530489
Durvalumab with Paclitaxel and AC I/II neoadjuvant TNBC October 2019 NCT02489448
Pembrolizumab with  Eribulin Ib/II metastatic TNBC January 2018 NCT02513472
Pembrolizumab and Nab-paclitaxel with or without
Carboplatin followed  by AC*
Ib neoadjuvant TNBC August 2017 NCT02622074

Immunotherapy and radiotherapy

Pembrolizumab  with Hypofractionated Radiotherapy I metastatic BC February 2017 NCT02303990
Pembrolizumab with Stereotactive Ablative Radiosurgery I oligometastatic BC September 2020 NCT02303366
Durvalumab and Tremelimumab with Hypofractionated
Radiotherapy
I metastatic BC December 2018 NCT02639026
Tremelimumab and brain irradiation I metastatic BC September 2017 NCT02563925

Immunotherapy and targeted therapy 

Atezolizumab with T-DM1 or Trastuzumab, Pertuzumab Ib metastaticHER2+BC§ August 2018 NCT02605915
Pembrolizumab with Trastuzumab I/II metastatic HER2+BC December 2017 NCT02129556
Durvalumab with Ibrutinib I/II metastatic BC June 2019 NCT02403271
Durvalumab with Selumetinib I metastatic BC April 2017 NCT02586987
Durvalumab with Olaparib or Cediranib I/II metastatic TNBC December 2019 NCT02484404
Pembrolizumab with JAK inhibitor (INCB039110) or
PI3K-delta inhibitor (INCB050465)
I metastatic TNBC June 2017 NCT02646748
Pembrolizumab with PLX3397 I/II metastatic TNBC July 2019 NCT02452424
Pembrolizumab with  Vorinostat and  Tamoxifen II metastatic ER+BC August 2017 NCT02395627
Nivolumab +/- Ipilimumab with Entinostat I metastatic HER2-BCII January 2017 NCT02453620

Combination immunotherapy

Nivolumab with  Ipilimumab I/II metastatic TNBC December 2017 NCT01928394
Durvalumab and Tremelimumab II metastatic HER2-BC September 2017 NCT02536794
Durvalumab and  Epacadostat I/II metastatic TNBC March 2018 NCT02318277
Pembrolizumab with Epacadostat I/II metastatic TNBC November 2017 NCT02178722
Atezolizumab with Varlimumab I/II metastatic TNBC June 2019 NCT02543645
Pembrolizumab and Enoblituzumab I metastatic TNBC August 2020 NCT02475213

Abbreviations: *AC: doxorubicin, cyclophosphamide; TNBC: triple negative breast cancer; BC: breast cancer;
§HER2+BC: HER2 positive breast cancer; IIHER2-BC: HER2 negative breast cancer; ER+BC: hormone receptor positive breast cancer

Tamkus et al.Oncology Discovery  2016 4:1DOI : 10.7243/2052-6199-4-1